Skip Header

14 results for author:"Whiteaker P." in Literature citations

Page 1 of 1

to top of page·  

Results Customize

› Repeat search in UniProtKB (1)

Function of human alpha3beta4alpha5 nicotinic acetylcholine receptors is reduced by the alpha5(D398N) variant.

George A.A., Lucero L.M., Damaj M.I., Lukas R.J., Chen X., Whiteaker P.

J. Biol. Chem. 287:25151-25162(2012) · Mapped (3)

Desensitization of alpha7 nicotinic receptor is governed by coupling strength relative to gate tightness.

Zhang J., Xue F., Whiteaker P., Li C., Wu W., Shen B., Huang Y., Lukas R.J., Chang Y.

J. Biol. Chem. 286:25331-25340(2011) · Mapped (13)

Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism.

Zhao-Shea R., Cohen B.N., Just H., McClure-Begley T., Whiteaker P., Grady S.R., Salminen O., Gardner P.D., Lester H.A., Tapper A.R.

FASEB J. 24:49-57(2010) · Mapped (5)

In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors.

Drenan R.M., Grady S.R., Whiteaker P., McClure-Begley T., McKinney S., Miwa J.M., Bupp S., Heintz N., McIntosh J.M., Bencherif M. et al.

Neuron 60:123-136(2008) · Mapped (3)

Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Nashmi R., Xiao C., Deshpande P., McKinney S., Grady S.R., Whiteaker P., Huang Q., McClure-Begley T., Lindstrom J.M., Labarca C. et al.

J. Neurosci. 27:8202-8218(2007) · Mapped (5)

Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers.

Brown R.W., Collins A.C., Lindstrom J.M., Whiteaker P.

J. Neurochem. 103:204-215(2007) · Mapped (4)

Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist.

Whiteaker P., Christensen S., Yoshikami D., Dowell C., Watkins M., Gulyas J., Rivier J., Olivera B.M., McIntosh J.M.

Biochemistry 46:6628-6638(2007) · UniProtKB (1)

Immunolabeling demonstrates the interdependence of mouse brain alpha4 and beta2 nicotinic acetylcholine receptor subunit expression.

Whiteaker P., Cooper J.F., Salminen O., Marks M.J., McClure-Begley T.D., Brown R.W., Collins A.C., Lindstrom J.M.

J. Comp. Neurol. 499:1016-1038(2006) · Mapped (2)

Novel seizure phenotype and sleep disruptions in knock-in mice with hypersensitive alpha 4* nicotinic receptors.

Fonck C., Cohen B.N., Nashmi R., Whiteaker P., Wagenaar D.A., Rodrigues-Pinguet N., Deshpande P., McKinney S., Kwoh S., Munoz J. et al.

J. Neurosci. 25:11396-11411(2005) · Mapped (5)

Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.

Gotti C., Moretti M., Clementi F., Riganti L., McIntosh J.M., Collins A.C., Marks M.J., Whiteaker P.

Mol. Pharmacol. 67:2007-2015(2005) · Mapped (3)

Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization.

Tapper A.R., McKinney S.L., Nashmi R., Schwarz J., Deshpande P., Labarca C., Whiteaker P., Marks M.J., Collins A.C., Lester H.A.

Science 306:1029-1032(2004) · Mapped (5)

The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors.

Cui C., Booker T.K., Allen R.S., Grady S.R., Whiteaker P., Marks M.J., Salminen O., Tritto T., Butt C.M., Allen W.R. et al.

J. Neurosci. 23:11045-11053(2003) · Mapped (3)

A polymorphism in the mouse neuronal alpha4 nicotinic receptor subunit results in an alteration in receptor function.

Dobelis P., Marks M.J., Whiteaker P., Balogh S.A., Collins A.C., Stitzel J.A.

Mol. Pharmacol. 62:334-342(2002) · Mapped (5)

Involvement of the alpha3 subunit in central nicotinic binding populations.

Whiteaker P., Peterson C.G., Xu W., McIntosh J.M., Paylor R., Beaudet A.L., Collins A.C., Marks M.J.

J. Neurosci. 22:2522-2529(2002) · Mapped (4)

to top of page·

Page 1 of 1